Skip to content

Study · Measured the body's own peptide · 1984

2 results

Improvement in clinical condition and thymus morphologic features associated with growth hormone treatment of immunodeficient dwarf dogs.

Roth JA, Kaeberle ML, Grier RL, Hopper JG, Spiegel HE, McAllister HA

American journal of veterinary research1 Jun 1984Cited by 23 (Europe PMC)

PMID6742575 (opens in a new tab)PepBankPUB-06742575
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Natural levels measured2

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In immunodeficient dwarf Weimaraner pups, growth hormone therapy was not associated with a consistent increase in serum thymosin alpha‑1 concentration.

    In plain wordsIn dwarf dog pups, growth hormone treatment did not consistently raise the body's own thymosin alpha‑1 in blood.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeChange in serum thymosin alpha 1 after growth hormone therapy
    Study

    dogn = 2

    immunodeficient Weimaraner dwarf pups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Growth hormone therapy was not associated with a consistent increase in serum thymosin alpha 1 concentration or lymphocyte blastogenic responsiveness to mitogens.
    1 context sentence
    Summary · context
    Growth hormone therapy (0.1 mg/kg of body weight/dose, 14 doses) during a 1-month period in 2 immunodeficient dwarf pups resulted in clinical improvement and a marked increase in the thickness and cellularity of the cortex of the thymus.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Other

    In immunodeficient dwarf Weimaraner pups, serum thymosin alpha‑1 was not deficient before growth hormone therapy.

    In plain wordsIn dwarf dog pups, the body's own thymosin alpha‑1 in blood was not low before growth hormone treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeSerum thymosin alpha 1 before growth hormone therapy
    Study

    dogn: not reported in source

    immunodeficient Weimaraner dwarf pups
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Immunodeficient dwarf pups were not deficient in serum thymosin alpha 1 before GH therapy.
    1 context sentence
    Summary · context
    Immunodeficient dwarfism in Weimaraner dogs was characterized by failure to grow, emaciation, growth hormone (GH) deficiency, decreased lymphocyte blastogenic responsiveness to mitogens, lack of thymus cortex, and recurrent infections usually resulting in death.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.